{"id":"NCT00855309","sponsor":"Wake Forest University Health Sciences","briefTitle":"Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia","officialTitle":"Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2013-11","completion":"2013-11","firstPosted":"2009-03-04","resultsPosted":"2013-11-25","lastUpdate":"2018-07-06"},"enrollment":112,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Herpes Simplex"],"interventions":[{"type":"DRUG","name":"acyclovir sodium","otherNames":[]}],"arms":[{"label":"Arm I","type":"EXPERIMENTAL"},{"label":"Arm II","type":"EXPERIMENTAL"}],"summary":"RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in patients with neutropenia.\n\nPURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is comparing two doses of acyclovir in preventing herpes simplex virus infection in patients with neutropenia.","primaryOutcome":{"measure":"Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine â‰¥ 2 Times the Patient's Baseline","timeFrame":"24 hours","effectByArm":[{"arm":"Arm I","deltaMin":2,"sd":null},{"arm":"Arm II","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":56},"commonTop":["Nephrotoxicity"]}}